FAS and neoplasm: Recently, it has been shown that scenarios where antigen loss or antigen mutation in highly heterogenous tumors interferes with the binding of scFv of a designated CAR-T, FasL-Fas-mediated off-target (bystander) killing of antigen-negative tumor cells is critical in human clinical trials as well as in murine studies [16].